General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 708–5453. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket (EDIS) at *https://edis.usitc.gov.* For help accessing EDIS, please email *EDIS3Help@usitc.gov.* General information concerning the Commission may also be obtained by accessing its internet server at *https://www.usitc.gov.* Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205–1810.

SUPPLEMENTARY INFORMATION: The Commission instituted Investigation No. 337–TA–1422 (''the 1422 investigation'') on November 5, 2024, and instituted Investigation No. 337–TA–1425 (''the 1425 investigation'') on December 9, 2024, based on complaints filed by Trina Solar (U.S.), Inc. of Fremont, CA, Trina Solar US Manufacturing Module 1, LLC of Wilmer, TX, and Trina Solar Co., Ltd. of Xinbei District, China (collectively, ''Trina'' or ''Complainants''). 89 FR 87889–90 (Nov. 5, 2024); 89 FR 97653–54 (Dec. 9, 2024). The complaints, as supplemented, collectively allege violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain TOPCon solar cells, modules, panels, components thereof, and products containing the same by reason of infringement of claims 1–11 of U.S. Patent No. 9,722,104 (''the '104 patent'') and claims 1–17 of U.S. Patent No. 10,230,009 (''the '009 patent''). The complaints further allege that a domestic industry exists. The Commission's notices of investigation collectively named as respondents: Runergy USA Inc., of Pleasanton, CA; Runergy Alabama Inc., of Huntsville, AL; Jiangsu Runergy New Energy Technology, Co., Ltd., of Yangcheng City, China; Adani Solar USA Inc., of Irving, TX; Adani Green Energy Ltd., of Ahmedabad, India; CSI Solar Co., Ltd., of Suzhou, China; Canadian Solar Inc., of West Guelph, Canada; Canadian Solar (USA) Inc., of Walnut Creek, CA; Canadian Solar Manufacturing (Thailand) Co., Ltd., of Bo Win, Thailand; Canadian Solar US Module Manufacturing Corporation, of Mesquite, TX; and Recurrent Energy Development Holdings, LLC, of Austin, TX. The Office of Unfair Import Investigations is participating in the investigations. *Id.*

On January 21, 2025, the Commission consolidated the 1422 investigation and the 1425 investigation. Inv. No. 337–TA–1422, Order No. 5 (Dec. 20, 2024) and Inv. No. 337–TA–1425, Order No. 4 (Dec. 20, 2024), *unreviewed by* Comm'n Notice (Jan. 21, 2025).

On January 31, 2025, the Commission determined not to review Order No. 8 granting Trina's unopposed motion to terminate the investigation as to Adani Green Energy Ltd. and to add Mundra Solar PV Ltd. as a respondent. *See* Order No. 8 (Jan. 14, 2025), *unreviewed by* Comm'n Notice (Jan. 31, 2025).

On February 12, 2025, the Commission determined not to review Order No. 9 amending the target date to May 20, 2026. *See* Order No. 9 (Jan. 15, 2025), *unreviewed by* Comm'n Notice (Feb. 12, 2025).

On February 13, 2025, the Commission determined not to review Order No. 7 granting Trina's unopposed motion to withdraw the complaint and terminate the investigation as to respondent Recurrent Energy Development Holdings LLC. *See* Order No. 8 (Jan. 14, 2025), *unreviewed by* Comm'n Notice (Feb. 13, 2025).

On June 17, 2025, the Commission determined not to review Order No. 15 granting Trina's unopposed motion to amend the complaint and notice of investigation to reflect a corporate name change by Trina Solar US Manufacturing Module 1, LLC to T1 G1 Dallas Solar Module (Trina) LLC. *See* Order No. 15 (May 23, 2025), *unreviewed by* Comm'n Notice (June 17, 2025).

On August 26, 2025, the Commission determined not to review Order No. 20 granting Trina's unopposed motion to terminate the investigation in part by withdrawing claim 11 of the '104 patent and claim 14 of the '009 patent. Order No. 20 (Aug. 7, 2025), *unreviewed by* Comm'n Notice (Aug. 26, 2025).

On December 8, 2025, the Commission determined not to review Order No. 34 extending the target date for completion of the investigation to August 18, 2026. Order No. 34 (Nov. 19, 2025), *unreviewed by* Comm'n Notice (Dec. 8, 2025).

On December 9, 2025, the Commission determined not to review Order No. 35 granting Trina's unopposed motion to terminate the investigation in part by withdrawing claims 2–5 and 9–10 of the '104 patent and claims 2, 3, 5, 7, 11–13, and 16 of the '009 patent. Order No. 35 (Nov. 19, 2025), *unreviewed by* Comm'n Notice (Dec. 9, 2025).

On January 15, 2026, the presiding administrative law judge issued the subject ID (Order No. 40) granting the parties' joint motion to terminate the investigation in its entirety. The ID found that the motion complied with Commission Rule 210.21(a)(1) (19 CFR 210.21(a)(1)) and that termination of the investigation was in the public interest.

No petitions for review of the ID were filed.

The Commission has determined not to review the subject ID. The investigation is terminated in its entirety.

The Commission vote for these determinations took place on February 10, 2026.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: February 11, 2026.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2026–02949 Filed 2–12–26; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1659]

Bulk Manufacturer of Controlled Substances Application: Scottsdale Research Institute

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Scottsdale Research Institute has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before April 14, 2026. Such persons may also file a written request for a hearing on the application on or before April 14, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for

lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov*. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on January 8, 2026, Scottsdale Research Institute, 12815 North Cave Creek Road, Phoenix, Arizona 85022, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Psilocybin	7437	I
Psilocyn	7438	I

The company plans to bulk manufacture the listed controlled substances for internal research purposes and to support clinical trials. No other activities for these drug codes are authorized for this registration

Thomas Prevoznik,

Deputy Assistant Administrator.

[FR Doc. 2026–02909 Filed 2–12–26; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1650]

Bulk Manufacturer of Controlled Substances Application: Siemens Healthcare Diagnostics, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Siemens Healthcare Diagnostics, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before April 14, 2026. Such persons may also file a written request for a hearing on the application on or before April 14, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on January 14, 2026, Siemens Healthcare Diagnostics, Inc., 100 GBC Drive, Mailstop 108, Newark, Delaware 19702–2461, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Ecgonine	9180	II

The company plans to bulk manufacture the listed controlled substance in bulk to be used in the manufacture of the DEA exempt products. No other activity for this drug code is authorized for this registration.

Thomas Prevoznik,

Deputy Assistant Administrator.

[FR Doc. 2026–02911 Filed 2–12–26; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1661]

Importer of Controlled Substances Application: S&B Pharma LLC DBA Norac Pharma

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: S&B Pharma LLC DBA Norac Pharma has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before March 16, 2026. Such persons may also file a written request for a hearing on the application on or before March 16, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on January 13, 2026, S&B Pharma LLC DBA Norac Pharma, 405 South Motor Avenue, Azusa, California 91702, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
4-Anilino-N-phenethyl-4-piperidine (ANPP).	8333	II
Tapentadol	9780	II

The company plans to import intermediate forms of Tapentadol (9780) for further manufacturing prior to distribution to its customers. The company plans to import ANPP (8333) to bulk manufacture other controlled substances for distribution to its customers. No other activities for these drug codes are authorized for this registration.